Watson Pharmaceuticals Inc. said late Wednesday the Food and Drug Administration approved its drug Rapaflo for the treatment of urinary problems.
The drug is approved as a treatment for BPH, or benign prostatic hyperplasia, which has symptoms including decreased urine flow and more frequent urination.
Watson plans to launch the drug in early 2009. It estimates the U.S. market for all BPH drugs at about $2 billion annually.
Shares of Watson closed at $24.63 Wednesday.
The drug is approved as a treatment for BPH, or benign prostatic hyperplasia, which has symptoms including decreased urine flow and more frequent urination.
Watson plans to launch the drug in early 2009. It estimates the U.S. market for all BPH drugs at about $2 billion annually.
Shares of Watson closed at $24.63 Wednesday.
0 comments:
Post a Comment